5-氟-3-(4-哌啶基)-1,2-苯并异噁唑盐酸盐 | 84163-16-6

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 中文名称: 5-氟-3-(4-哌啶基)-1,2-苯并异噁唑盐酸盐
• 中文别名: 5-氟-3-(4-哌啶基)-1,2-苯并异恶唑盐酸盐；5-氟-3-(4-哌啶)-1,2-苯异恶唑盐酸盐
• 英文名称: 5-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole hydrochloride
• 英文别名: 5-fluoro-3-(piperidin-4-yl)-1,2-benzoxazole hydrochloride；4-(5-fluoro-1,2-benzisoxazol-3-yl)piperidine hydrochloride；5-fluoro-3-(4-piperidyl)-1,2-benzisoxazole hydrochloride；5-fluoro-3-piperidin-4-yl-1,2-benzoxazole;hydrochloride
• CAS: 84163-16-6
• 化学式: C₁₂H₁₃FN₂O*ClH
• mdl: MFCD06200879
• 分子量: 256.707
• InChiKey: HSOJFILHZZEWJT-UHFFFAOYSA-N

物化性质

• 熔点：
  300-301
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.73
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  38.1
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934999090

SDS

Name:	5-Fluoro-3-(4-piperidinyl)-1 2-benzisoxazole hydrochloride Material Safety Data Sheet
Synonym:	None Known
CAS:	84163-16-6

Section 1 - Chemical Product MSDS Name:5-Fluoro-3-(4-piperidinyl)-1 2-benzisoxazole hydrochloride Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
84163-16-6	5-Fluoro-3-(4-piperidinyl)-1,2-benziso	97+	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store protected from moisture. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 84163-16-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 300-301 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H13FN2O.HCl
Molecular Weight: 256.70

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions. Moisture sensitive.
Conditions to Avoid:
Dust generation, moisture.
Incompatibilities with Other Materials:
Oxidizing agents, bases.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, oxides of nitrogen, carbon dioxide, hydrogen fluoride gas.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 84163-16-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 84163-16-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 84163-16-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 84163-16-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氟-3-(4-哌啶基)-1,2-苯并异噁唑盐酸盐 在 四(三苯基膦)钯 、 potassium carbonate 、 三乙胺 作用下， 以 1,4-二氧六环 、 水 、 二甲基亚砜 为溶剂， 反应 10.0h， 生成 5-fluoro-3-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazole
  参考文献：
  名称：

  4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: Part 2. Pyridazine-based analogs

  摘要：

  Design, synthesis, and biological evaluation of pyridazine-based, 4-bicyclic heteroaryl-piperidine derivatives as potent stearoyl-CoA desaturase-1 (SCD1) inhibitors are described. In a chronic study of selected analog (3e) in Zucker fa/fa (ZF) rat, dose-dependent decrease of body weight gain and plasma fatty acid desaturation index (DI) in both C16 and C18 are also demonstrated. The results indicate that the plasma fatty acid DI may serve as an indicator for direct target engagement and biomarker for SCD1 inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.075
• 作为产物：
  描述：

  5-氟-3-(4-哌啶基)-1,2-苯并异噁唑 在 盐酸 作用下， 以 乙醚 为溶剂， 反应 0.5h， 生成 5-氟-3-(4-哌啶基)-1,2-苯并异噁唑盐酸盐
  参考文献：
  名称：

  4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: Part 2. Pyridazine-based analogs

  摘要：

  Design, synthesis, and biological evaluation of pyridazine-based, 4-bicyclic heteroaryl-piperidine derivatives as potent stearoyl-CoA desaturase-1 (SCD1) inhibitors are described. In a chronic study of selected analog (3e) in Zucker fa/fa (ZF) rat, dose-dependent decrease of body weight gain and plasma fatty acid desaturation index (DI) in both C16 and C18 are also demonstrated. The results indicate that the plasma fatty acid DI may serve as an indicator for direct target engagement and biomarker for SCD1 inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.075

文献信息

• Condensed thiophene compound and pharmaceutical use thereof
  申请人：Yoshitomi Pharmaceutical Industries, Ltd.

  公开号：US05532240A1

  公开（公告）日：1996-07-02

  A condensed thiophene compound represented by general formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein ring S represents a thiophene ring; R.sup.1 represents hydrogen, halogen, alkyl, etc.; R.sup.2 represents hydrogen, alkyl, acyl, etc.; G represents --CH.sub.2 --, --CH(OH)--, --CO--, etc.; Q represents alkylene; T represents --N(Rb)(Rc) (wherein Rb, Rc represents each alkyl etc.; or alternatively Rb and Rc are combined together to form cyclic amino); D represents --CH.sub.2 -- or --S--; A and B represent each carbonyl or thiocarbonyl, or are null; and m and n represent each 0, 1 to 4, provided that m+n represents an integer of 4 or less. This compound is useful as an antipsychotic drug having a reduced extrapyramidal side effect.

  一种缩合噻吩化合物，其通式为：##STR1## 或其药学上可接受的盐，其中环S代表噻吩环；R1代表氢、卤素、烷基等；R2代表氢、烷基、酰基等；G代表--CH2--、--CH(OH)--、--CO--等；Q代表亚烷基；T代表--N(Rb)(Rc)（其中Rb、Rc各自代表烷基等；或者Rb和Rc结合形成环状氨基）；D代表--CH2--或--S--；A和B各自代表羰基或硫羰基，或者为空；m和n各自代表0、1至4，条件是m+n代表4或以下的整数。该化合物作为具有减少锥体外系副作用的抗精神病药物是有用的。
• (4-Piperidyl)-substituted phenyl ketones
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US04408053A1

  公开（公告）日：1983-10-04

  Novel 3-(4-piperidyl)-1,2-benzisoxazoles, intermediates and processes for the preparation thereof, and methods for alleviating pain utilizing compounds or compositions thereof are disclosed.

  本发明公开了3-(4-哌啶基)-1,2-苯并异噁唑类化合物、中间体及其制备方法，以及利用这些化合物或组合物缓解疼痛的方法。
• Oximes of 4-benzoyl-piperidines
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US04408054A1

  公开（公告）日：1983-10-04

  Novel 3-(4-piperidyl)-1,2-benzisoxazoles, intermediates and processes for the preparation thereof, and methods for alleviating pain utilizing compounds or compositions thereof are disclosed.

  本发明公开了3-(4-哌啶基)-1,2-苯并异噁唑类化合物、中间体和制备方法，以及利用这些化合物或组合物缓解疼痛的方法。
• 3-(4-Piperidinium)-1,2-benzisoxazoles
  申请人：Hoechst-Roussel Pharmaceuticals, Inc.

  公开号：US04469869A1

  公开（公告）日：1984-09-04

  Novel 3-(4-piperidyl)-1,2-benzisoxazoles, intermediates and processes for the preparation thereof, and methods for alleviating pain utilizing compounds or compositions thereof are disclosed.

  本发明公开了3-(4-哌啶基)-1,2-苯并异噁唑类化合物、中间体和其制备方法，以及利用该化合物或其组合物缓解疼痛的方法。
• 3-(4-Piperidyl)-1,2-benzisoxazoles
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US04528376A1

  公开（公告）日：1985-07-09

  Novel 3-(4-piperidyl)-1,2-benzisoxazoles, intermediates and processes for the preparation thereof, and methods for alleviating pain utilizing compounds or compositions thereof are disclosed.

  本发明公开了一种Novel 3-(4-哌啶基)-1,2-苯并异噁唑，中间体及其制备方法，并公开了利用该化合物或其组合物缓解疼痛的方法。